Next-Generation Vaccine and Immunotherapy

Dear Colleagues,

The COVID-19 pandemic has brought about significant changes to our world, impacting our daily lives in numerous ways. With unrestricted human travel and rapid air transportation, pandemics have become a constant concern. However, this situation has also accelerated the development of vaccines. Today, most people have received vaccinations against COVID-19, and the introduction of advanced mRNA-based formulations has ushered in a new era in vaccine technology. While this shift holds great potential for improving vaccine effectiveness, it also requires careful consideration of the long-term effects, both positive and negative, of mRNA-based vaccination. The widespread threat posed by pathogens and cancer to both humans and animals underscores the importance of cooperation within the scientific community in the fight against these common enemies. 

Within this dedicated Special Issue, our focus coalesces around the realms of next-generation vaccine interventions and avant-garde immunotherapeutic modalities, each targeted at addressing the virulent challenges posed by pathogens and malignancies. We cordially invite scholarly contributions encompassing the following investigative domains:

• Proof of concept pertaining to next-generation vaccines and immunotherapy;
• Fundamental explorations and clinical investigations into next-generation vaccine and immunotherapeutic modalities.

Dr. Takashi Imai
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• next-generation vaccine
• immunotherapy
• pathogens
• cancers